Specifications
Properties
Additional Info
Background
Specifications
| SPECIES REACTIVITY: | Human |
|---|---|
| HOMOLOGY: | Predicted species reactivity based on immunogen sequence: Mouse: (93%), Rat: (93%) |
| TESTED APPLICATIONS: | ELISA, ICC, WB |
| APPLICATIONS: | DRAK2 antibody can be used for detection of DRAK2 by Western blot 0.5 μg/mL. An approximately 45 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested. |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| POSITIVE CONTROL: | 1) Cat. No. 1205 - Jurkat Cell Lysate |
| 2) Cat. No. 17-005 - Jurkat Cell Slide | |
| SPECIFICITY: | It has no cross responses to DAP or ZIP kinases. The approximately 70 kDa band is probably non-related to DRAK2 although it is peptide blockable. |
| IMMUNOGEN: | DRAK2 antibody was raised against a 15 amino acid peptide near the carboxy terminus of human DRAK2. The immunogen is located within the last 50 amino acids of DRAK2. |
| HOST SPECIES: | Rabbit |
Properties
| PURIFICATION: | DRAK2 Antibody is Ion exchange chromatography purified. |
|---|---|
| PHYSICAL STATE: | Liquid |
| BUFFER: | DRAK2 Antibody is supplied in PBS containing 0.02% sodium azide. |
| CONCENTRATION: | batch dependent |
| STORAGE CONDITIONS: | DRAK2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| CLONALITY: | Polyclonal |
| ISOTYPE: | IgG |
| CONJUGATE: | Unconjugated |
Additional Info
| ALTERNATE NAMES: | DRAK2 Antibody: DRAK2, DRAK2, DAP kinase-related apoptosis-inducing protein kinase 2 |
|---|---|
| ACCESSION NO.: | AB011421 |
| PROTEIN GI NO.: | 3834355 |
| OFFICIAL SYMBOL: | STK17B |
| GENE ID: | 9262 |
Background
| BACKGROUND: | DRAK2 Antibody: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. |
|---|---|
| REFERENCES: | 1) Sanjo H, Kawai T, Akira S. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J Biol Chem 1998;273:29066-71 (RD1299) |
For Research Use Only
